X4 Pharmaceuticals Announces Late-Breaking Abstract of WHIM Phase 3 Clinical Data Accepted for Oral Presentation at the 2023 Annual Meeting of the…

X4 Pharmaceuticals

X4 to host virtual investor event on Tuesday, May 16

CIS oral presentation to take place on Sunday, May 21

BOSTON, April 12, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel small molecule therapeutics to benefit patients with diseases of the immune system, today announced that its submitted late-breaker abstract entitled "Results of a Phase 3 Trial of an Oral CXCR4 Antagonist, Mavorixafor, for Treatment of Patients With WHIM Syndrome" has been accepted for oral presentation at the Annual Meeting of the Clinical Immunology Society (CIS), which is taking place May 18-21, 2023, in St. Louis, MO. New data related to clinical secondary endpoints, among other assessments, are to be presented.

In addition, X4 announced that the company will host a virtual event to present and discuss new data from the 4WHIM Phase 3 clinical trial at 4:00 pm ET on Tuesday, May 16, following expected publication of conference abstracts. In November 2022, X4 announced that the 4WHIM trial had met its primary endpoint and a key secondary endpoint, and that mavorixafor was generally well tolerated in the trial, with no treatment-related serious adverse events reported and no discontinuations for safety events. New data to be presented during the event will focus on additional secondary endpoints, including the impact of oral, once-daily mavorixafor on the rate, severity, and duration of infections, among other outcomes metrics, as measured during the 52-week trial period.

Additionally, the company expects to provide an update on its U.S. regulatory activities in support of its potential New Drug Application-submission for mavorixafor for the treatment of WHIM syndrome, which is expected early in the second half of 2023.

The X4 live-event webcast will be accessible on the investor relations section of the X4 website at http://www.x4pharma.com. Following the completion of the event, a replay will be available on the website.

Story continues

At the CIS Conference, Dr. Raffaele Badolato, Professor of Pediatrics at the University of Brescia (Italy) and an investigator in the 4WHIM clinical trial, will present at 11:30 am CT on Sunday, May 21. Although the session will only be accessible live to conference attendees, X4 will post the slides on its website concurrent with the presentation.

About Mavorixafor and WHIM SyndromeWHIM (warts, hypogammaglobulinemia, infections, and myelokathexis) syndrome is a rare, inherited, combined immunodeficiency disease caused by reduced mobilization and trafficking of white blood cells from the bone marrow due to over-signaling of the CXCR4/CXCL12 pathway. People with WHIM syndrome characteristically have very low blood levels of neutrophils (neutropenia) and lymphocytes (lymphopenia), and as a result, experience frequent, recurrent infections with a high risk of lung disease, refractory warts from underlying human papillomavirus (HPV) infection, limited antibody production due to low levels of immunoglobulin, and an increased risk of developing certain types of cancer. Mavorixafor is an investigational small-molecule antagonist of CXCR4 being developed as a once-daily oral therapy to correct the dysfunction resulting from the underlying causes of WHIM. For the WHIM indication, mavorixafor has been granted Breakthrough Therapy Designation, Fast Track Designation, and Rare Pediatric Designation in the U.S., and Orphan Drug Status in both the U.S. and European Union.

About the 4WHIM Phase 3 Clinical TrialThe 4WHIM Phase 3 clinical trial was a global, randomized, double-blind, placebo-controlled, multicenter study designed to evaluate the efficacy and safety of oral, once-daily mavorixafor in people with genetically confirmed WHIM syndrome. Originally designed to enroll 18-28 patients, the trial enrolled 31 patients aged 12 and older who received either 400 mg mavorixafor (n=14) or placebo (n=17) orally once daily for 52 weeks.

About X4 Pharmaceuticals X4 Pharmaceuticals is a late-stage clinical biopharmaceutical company focused on the discovery and development of novel therapies for people with diseases of the immune system. Our lead clinical candidate is mavorixafor, a small molecule antagonist of chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. Due to its ability to increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream, we believe that mavorixafor has the potential to provide therapeutic benefit across a variety of chronic neutropenic disorders, including WHIM (Warts, Hypogammaglobulinemia, Infections, and Myelokathexis) syndrome, a rare, primary immunodeficiency. Following announcement of positive top-line data from our global, pivotal, 4WHIM Phase 3 clinical trial, we are currently preparing a U.S. regulatory submission seeking approval of oral, once-daily mavorixafor in the treatment of people aged 12 years and older with WHIM syndrome. We are also currently evaluating mavorixafor in a Phase 2 clinical trial in people with certain chronic neutropenic disorders following positive results from a Phase 1b clinical trial of mavorixafor in people with congenital, idiopathic, or cyclic neutropenia. We continue to leverage our insights into CXCR4 and immune system biology at our corporate headquarters in Boston, Massachusetts and at our research center of excellence in Vienna, Austria. For more information, please visit our website at http://www.x4pharma.com.

Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995, as amended. These statements may be identified by the words may, will, could, would, should, expect, plan, anticipate, intend, believe, estimate, predict, project, potential, continue, target, or other similar terms or expressions that concern X4's expectations, strategy, plans, or intentions. Forward-looking statements include, without limitation, statements regarding the clinical progress of X4s pipeline development programs, including the anticipated New Drug Application submission for mavorixafor for the treatment of WHIM syndrome and the timing thereof. Any forward-looking statements in this press release are based on management's current expectations and beliefs. Actual events or results may differ materially from those expressed or implied by any forward-looking statements contained herein, including, without limitation, on account of uncertainties inherent in the initiation and completion of clinical trials and clinical development; the risk that trials and studies may not have satisfactory outcomes; the risk that the outcomes of preclinical studies or earlier clinical trials will not be predictive of later clinical trial results; the risk that initial or interim results from a clinical trial may not be predictive of the final results of the trial or the results of future trials; the potential adverse effects arising from the testing or use of mavorixafor or other product candidates; the risk that the Food and Drug Administration (FDA) may not support and accept a regulatory submission for mavorixafor, and that X4s interactions with the FDA may not have satisfactory outcomes; the risks related to X4s ability to raise additional capital; the impacts of macroeconomic conditions, including the COVID-19 pandemic, the conflict in Ukraine, rising inflation, and uncertain credit and financial markets on X4s business, clinical trials and financial position; and other risks and uncertainties, including those described in the section entitled Risk Factors in X4s Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on March 21, 2023, and in other filings X4 makes with the SEC from time to time. X4 undertakes no obligation to update the information contained in this press release to reflect new events or circumstances, except as required by law.

Contacts:Daniel Ferry (investors)Managing Director, LifeSci Advisorsdaniel@lifesciadvisors.com (617) 430-7576

Cherilyn Cecchini, M.D. (media)LifeSci Communicationsccecchini@lifescicomms.com

Here is the original post:
X4 Pharmaceuticals Announces Late-Breaking Abstract of WHIM Phase 3 Clinical Data Accepted for Oral Presentation at the 2023 Annual Meeting of the...

argenx Demonstrates Commitment to Redefining Treatment Goals … – GlobeNewswire

Amsterdam, the Netherlands [04/18/2023] argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will present six abstracts further demonstrating its long-term commitment to the generalized myasthenia gravis (gMG) community during the 75th American Academy of Neurology (AAN) Annual Meeting, which is taking place from April 22-27, 2023 in Boston, MA. The presentations include clinical and real-world efgartigimod data that demonstrate the potential of neonatal Fc receptor (FcRn) blockade in transforming treatment for gMG and other IgG-mediated autoimmune diseases.

Our presentations at AAN will showcase the depth of evidence we are generating in support of the clinical and real-world profile of efgartigimod to address the often-underappreciated needs of people living with gMG, said Luc Truyen, M.D. Ph.D., Chief Medical Officer, argenx. We have a unique opportunity to recalibrate expectations for patients and their supporters by setting a new standard for what well-controlled means in gMG and across autoimmunity more broadly.

Power of Individualized Dosing from Long-term Extension StudiesThe presentations include results from the open-label extension studies of VYVGART (efgartigimod alfa-fcab) and subcutaneous (SC) efgartigimod following long-term treatment in ADAPT+ (217.5 patient-years follow-up) and ADAPT-SC+ (72 patient-years follow-up). Long-term treatment, administered in individualized dosing cycles, led to consistent and repeatable reductions in IgG antibody levels and improved clinical outcomes.

A cross-indication review of the safety profile of efgartigimod will also be presented across multiple IgG-mediated autoimmune diseases, reinforcing the consistent safety profile observed with efgartigimod.

Potential in Patients Early in gMG Disease CourseA new exploratory analysis will be presented from the ADAPT Phase 3 trial showing that a greater percentage of gMG patients with fewer than three years disease duration were responders and achieved minimum symptom expression (MSE) compared with placebo.

New Opportunities with Patient Support ProgramsAs part of its commitment to address access for gMG patients impacted by social determinants of health challenges, argenx will present quantitative and qualitative research that identified potential opportunities to expand patient support program offerings, including the establishment of an information hotline and symptom tracking app, a patient mentoring program, an innovative giving strategy and broadened awareness campaigns of nurse case manager services.

Details for the poster presentations are as follows:

Title: Long-Term Safety, Tolerability, And Efficacy of Efgartigimod in Patients with Generalized Myasthenia Gravis: Concluding Analyses from the ADAPT+Session Date & Time: Oral Presentation - Sunday, April 23 at 2:00pm ETPresenter: Dr. Mamatha PasnoorAbstract Number: S5.006

Title: Long-Term Safety, Tolerability, and Efficacy of Subcutaneous Efgartigimod PH20 in Patients with Generalized Myasthenia Gravis: Interim Results of the ADAPT-SC+ StudySession Date & Time: Poster Session 1, Sunday, April 23, 8-9 am ETPresenter: Dr. James F. HowardAbstract Number: P1.5-014

Title: Dose Selection and Clinical Development of Efgartigimod Ph20 Subcutaneous Inpatients With Generalized Myasthenia GravisSession Date & Time: Poster Session 1, Sunday, April 23, 8-9 am ETPresenter: Dr. George LiAbstract Number: P1.5-017

Title: Overview of the Safety Profile from Efgartigimod Clinical Trials in Participants with Diverse IgG-Mediated Autoimmune DiseasesSession Date & Time: Poster Session 1, Sunday, April 23, 8-9 am ETPresenter: Dr. Kelly GwathmeyAbstract Number: P1.5-001

Title: Efgartigimod Demonstrates Consistent Improvements in Generalized Myasthenia Gravis Patients of Shorter Disease DurationSession Date & Time: Poster Session 1, Sunday, April 23, 8-9 am ETPresenter: Dr. Vera BrilAbstract Number: P1.5-015

Title: Patient Support Program Enhancements In Patients Diagnosed With Generalized Myasthenia Gravis Facing Social Determinants of Health ChallengesSession Date & Time: Poster Session 4, Monday, April 24, 8-9 am ETPresenter: Dr. Tom HughesAbstract Number: P4.9-006

See the full Prescribing Information for VYVGART in the U.S., which includes the below Important Safety Information. For more information related to VYVGART in Japan, visit argenx.jp.

Important Safety Information for VYVGART (efgartigimod alfa-fcab) intravenous (IV) formulation (U.S. prescribing information)

What is VYVGART (efgartigimod alfa-fcab)?VYVGART is a prescription medicine used to treat a condition called generalized myasthenia gravis, which causes muscles to tire and weaken easily throughout the body, in adults who are positive for antibodies directed toward a protein called acetylcholine receptor (anti-AChR antibody positive).

What is the most important information I should know about VYVGART?VYVGART may cause serious side effects, including:

Before taking VYVGART, tell your health care provider about all of your medical conditions, including if you:

Tell your health care provider about all the medicines you take, including prescription and over- the-counter medicines, vitamins, and herbal supplements.

What are the common side effects of VYVGART?

The most common side effects of VYVGART are respiratory tract infection, headache, and urinary tract infection.

These are not all the possible side effects of VYVGART. Call your doctor for medical advice about side effects. You may report side effects to the US Food and Drug Administration at 1- 800-FDA-1088.

Please see the full Prescribing Information for VYVGART and talk to your doctor.

About Generalized Myasthenia GravisGeneralized myasthenia gravis (gMG) is a rare and chronic autoimmune disease where IgG autoantibodies disrupt communication between nerves and muscles, causing debilitating and potentially life-threatening muscle weakness. Approximately 85% of people with MG progress to gMG within 24 months, where muscles throughout the body may be affected. Patients with confirmed AChR antibodies account for approximately 85% of the total gMG population.

About VYVGART (efgartigimod alfa-fcab)VYVGART is a human IgG1 antibody fragment that binds to the neonatal Fc receptor (FcRn), resulting in the reduction of circulating immunoglobulin G (IgG) autoantibodies. It is the first and only approved FcRn blocker. VYVGART is approved in the United States and Europe for the treatment of adults with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive and in Japan for the treatment of adults with gMG who do not have sufficient response to steroids or non-steroidal immunosuppressive therapies (ISTs). VYVGART is being studied in adults with primary immune thrombocytopenia (ITP) and other IgG autoantibody-mediated diseases.

About argenxargenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first-and-only approved neonatal Fc receptor (FcRn) blocker in the U.S., the EU and UK, and Japan. The Company is evaluating efgartigimod in multiple serious autoimmune diseases and advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit http://www.argenx.com and follow us on LinkedIn, Twitter, and Instagram.

For further information, please contact:

Media:Erin Murphyemurphy@argenx.com

Investors:Beth DelGiaccobdelgiacco@argenx.com

Forward Looking StatementsThe contents of this announcement include statements that are, or may be deemed to be, forward-looking statements. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms believes, hope, estimates, anticipates, expects, intends, may, will, or should and include statements argenx makes concerning argenxs long-term commitment to the generalized myasthenia gravis (gMG) community, the potential of neonatal Fc receptor (FcRn) blockade in transforming treatment for gMG and other IgG-mediated autoimmune diseases, the expected long-term safety, tolerability and efficacy of VYVGART (efgartigimod alfa-fcab) in adult patients with gMG; and potential opportunities to expand patient support program offerings. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. argenxs actual results may differ materially from those predicted by the forward-looking statements as a result of various important factors. A further list and description of these risks, uncertainties and other risks can be found in argenxs U.S. Securities and Exchange Commission (SEC) filings and reports, including in argenxs most recent annual report on Form 20-F filed with the SEC as well as subsequent filings and reports filed by argenx with the SEC. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. argenx undertakes no obligation to publicly update or revise the information in this press release, including any forward-looking statements, except as may be required by law.

See the article here:
argenx Demonstrates Commitment to Redefining Treatment Goals ... - GlobeNewswire

WVU Today | WVU research team steers students through murky … – WVU Today

West Virginia University researchers are studying how high school seniors and college students can utilize ChatGPT to learn how to code, while recognizing the potential shortcomings of the AI-powered chatbot. (WVU Photo/Alyssa Reeves)

West Virginia University researchers are preparing high school seniors and college students to harness the power of ChatGPT, the popular artificial intelligence chatbot, through coding while addressing the platforms potential shortcomings.

In a paper published in Quantitative Biology, a team led by Gangqing Michael Hu, assistant professor in the WVU School of Medicine Department of Microbiology, Immunology and Cell Biology, explored how they could help students overcome the fear of learning code and enhance their critical thinking skills.

This is like kids wading in the muddy shoreline seeking beautiful seashells, Hu said. The kids are the beginning students and the muddy shoreline is ChatGPT. The beautiful seashells represent all the attractive opportunities which beginners cannot resist. But the ChatGPT shoreline is muddy with challenges such as the uncertainty from the chatbots response including misleading artifacts and students overreliance on AI for coding.

ChatGPT produces human-like responses to text-based conversations and is being used by multiple companies to respond to customer inquiries and provide general information. Anyone can use it to seek information on a plethora of subjects.

One of the responses from ChatGPT can be code, and in this case the platform becomes a coding tool through prompting.

This is a new tool of learning coding and there are some misconceptions, Hu said. Students may think coding is not important because of prompting or they may have a fear in trying to learn it. We need to educate them on the purpose of this chatbot-assisted learning. Because some of the code from the chatbot can be wrong, students need to use critical thinking to be able to tell if the answer is correct and, if it is not, how to find a solution.

One of the biggest drawbacks to ChatGPT is that generated responses to questions can be either correct, incorrect or incomplete. In fact, it takes a human to provide carefully crafted prompts to fully harness the tool in providing valid and robust results.

Inspired by adaptive learning in educational literature, the team used the OPTIMAL model to facilitate chatbot-aided scientific data analysis. OPTIMAL, which stands for Optimization of Prompts Through Iterative Mentoring and Assessment, involves a series of steps to improve communication with a chatbot. In this case, it was geared toward bioinformatics, the science of collecting and analyzing large amounts of biological, medical and health information. Researchers say the model can be used for other purposes as well, such as finance and economics.

The OPTIMAL model is like rubber boots for the children to wear at the muddy shoreline, Hu said. The boots protect the kids from getting dirty much like the model is a protective mechanism to prevent the students from being misled by inaccurate information from the chatbot. The model aims to improve both coding skills and prompting skills through an iterative communication with a chatbot guided by critical thinking and assessment.

Following the OPTIMAL model, students review all the information needed for input and receive guidance on how to create a set of draft prompts. Once they input the prompt, the chatbot produces code and students are ready to give it a test.

If error messages result after running the code, students must evaluate the error and determine the best way to proceed, such as instructing the chatbot to revise the code or debugging the code manually.

The process continues until the code no longer issues errors and outputs a result for critical assessment. At the end of the session, students reflect on the entire communication process and review the code to identify any missing details to finalize the prompts.

The research team found that merely using the chatbot as a code-generating tool may limit creative thinking and that reviewing the code at the end of each session is just as important as optimizing the prompts.

The work brought together researchers from a spectrum of disciplines: Evelyn Shue, student volunteer in the Department of Microbiology, Immunology and Cell Biology; Bingxin Li, WVU John Chambers College of Business and Economics; Xin Li, WVU Benjamin M. Statler College of Engineering and Mineral Resources; Zifeng Feng, University of Texas at El Paso; and Li Liu, Arizona State University.

The team plans to evaluate the OPTIMAL models effectiveness in enhancing traditional bioinformatics education for beginners in the classroom.

This assessment should encompass improvements in coding skills, prompting skills, problem-solving abilities, and critical thinking during interactions with a chatbot, Hu said.

Future research will delve into more profound insights and strategies on applying ChatGPT to precision education.

There are certainly other sorts of rubber boots, Hu said.

-WVU-

ls/04/13/23

MEDIA CONTACT: Jake StumpDirectorWVU Research Communications304-293-5507; jake.stump@mail.wvu.edu

Call 1-855-WVU-NEWS for the latest West Virginia University news and information from WVUToday.

Follow @WVUToday on Twitter.

Original post:
WVU Today | WVU research team steers students through murky ... - WVU Today

Post-doctoral researcher in yeast cell biology job with UNIVERSITY … – Times Higher Education

The De Wulf lab at the Department of Cellular, Computational, and Integrative Biology (CIBIO), University of Trento, Italy, is looking for an outstanding, highly motivated post-doctoral scientist to study the activity of a conserved oncogenic kinase in the budding yeast Saccharomyces cerevisiae. The research project wishes to understand how this kinase regulates (peri)centromeric chromatin and telomeres to ensure timely kinetochore assembly, chromosome transmission, and cellular aging.

For publications related to the topic, see: Bock LJ et al (2012) Nature Cell Biology, Iacovella MG et al (2015) Nature Communications, Iacovella MG et al (2018) Nucleic Acids Research, Berto G et al (2019) Current Genetics, Jurikov K et al. (2021) Trends in Genetics. More details of currently work (Nature Communications (2023), in press) and the proposed project itself will be gladly provided upon request.

Please visit our website for more information on the lab s research, and publications: http://www.cibio.unitn.it/510/chromosome-segregation-biology

The offer is a 1-year post-doctoral research contract, that can be further extended after the first 1-year evaluation.

Read more here:
Post-doctoral researcher in yeast cell biology job with UNIVERSITY ... - Times Higher Education

expert reaction to study looking at creating embryo-like structures … – Science Media Centre

April 6, 2023

A study published in Cell Stem Cell looks at the generation of embryo-like structures from monkey embryonic stem cells.

Prof Magdalena Zernicka-Goetz, Bren Professor of Biology and Biological Engineering, California Institute of Technology; and Professor of Mammalian Development and Stem Cell Biology, University of Cambridge, said:

This is an exciting development building on work from our own and other labs showing the importance of establishing interactions between embryonic and extra-embryonic stem cells to establish models of the mammalian embryo at pre-and early post-implantation stages. The excitement of this study is not only that embryos generated from monkey stem cells provide a close model for human embryos, but monkeys are also experimentally tractable.

The authors follow approaches that have been previously used to direct embryonic stem cells into a naive state, and then use treatments that allow the nave monkey ES cells to form extra-embryonic cell types. Together these cells assemble into blastoids, structures resembling blastocysts, that are able to develop in vitro into structures with a striking resemblance to the embryonic disc at gastrulation, both in morphology and gene expression. The blastoids also appear to implant into foster monkey mothers but, in common with similar structures in the mouse, development appears restricted.

This study is a hugely encouraging development in the study of primate embryo models.

The paper is excellent and an important step forward but still the stem cell derived embryos have a limited developmental potential, as the authors state themselves. Nevertheless, it is an important step in the very exciting field of enormous potential for understanding how the embryo develops and why so many pregnancies fail.

Prof Roger Sturmey, Professor of Reproductive Medicine, Hull York Medical School, University of Hull, said:

The work by Li and colleagues is an impressive technical achievement that has demonstrated the possibility that embryonic stem cells from a primate can be persuaded to form structures that mirror many features of early embryos.

Similar achievements have already been reported in other species, however this work assesses the primate embryo-like structures in detail and gives new insights into how the cell lineages families of cells that constitute the early embryo can be generated from stem cells.

Remarkably, when cultured in a laboatory, the embryo-like structures are able to replicate a number of key developmental features, most notably the formation of cells that resemble the primordial germ cells the cells that can produce gametes as well as the formation of a structure similar to the so-called primitive streak. When transferred into a recipient macaque uterus, these embryo-like structures were able to generate components of a pregnancy response, but were unable to develop, indicating that while these structures do share many features with competent embryos, there are still aspects of early development that differ between competent embryos and stem-cell derived models, preventing full development.

The work by Li and colleagues will offer important new tools in our understanding of the earliest stages of embryo development, but also highlight the need for guidance in this area, something that scientists in the UK are actively working on.

Prof Alfonso Martinez Arias, ICREA Senior Research Professor, Department of Experimental and Health Sciences, Universitat Pompeu Fabra (UPF), said:

This is a timely study.

About half of human pregnancies fail during the proliferation of the zygote and the implantation of the blastocyst. Understanding the causes of this failure rate will impact human fertility and IVF success. In part to address this need, over the last few years, a number of Embryonic Stem (ES) cell models of early mammalian development have been created in the lab. Amidst these, mouse and human blastoids mimic mammalian blastocysts and as such can play an important role in understanding the process of implantation. Blastoids have been derived from mouse and human ES cells.

For these studies to go forward there is a need to develop a proper test for the function of the blastocyst: its implantation into the uterus. In the case of mouse blastoids this can be tested by implanting them into females. However, there is no such a test for human blastoids since, for obvious reasons, it is not possible to implant them into a human uterus. And yet there is a need to develop a system to study these structures in humans. Mouse reproductive biology and implantation are very different from human, which means that while an excellent system to find principles, the mouse is not useful for the specifics of this process; and this is what matters. It is this vacuum of a system to study human implantation and peri-implantation development that is addressed in the present study.

Following protocols established for human blastoids, macaque blastoids are made from nave stem cells and their potential is tested in two ways. One, by culturing them in vitro up to gastrulation stages and the other, by placing them in the uterus of a macaque foster mother. The idea behind this system is that it has reduced ethical barriers compared to human and therefore might provide an experimental system to test the potential of blastoids fully and, in the long term, to study infertility. The work is well conducted and the result is clear: although at the level of single cells macaque blastoids bear a strong resemblance to blastocysts, they do not behave as blastocysts. Although they implant and initiate gastrulation, they do not reach the end of this process. In vitro, blastoids cultured to form an epiblast and to undergo gastrulation, display progressive problems over time and, though they reach early stages of gastrulation, it is difficult to see in their data how faithful they are to an early gastrula. In one important experiment they implant some of these into female macaques and follow their progress with ultrasound. It appears as if they might perform well in the early stages of implantation, and the release of progesterone is a sign that something has gone well, but then, they disappear after about a week.

So, the important result of this work is that we are not close to generating blastoids that can be recognised as blastocysts by the mother. Definitely an important proof of principle but the lesson is that there is work to do.

An important difference between a blastoid and a blatocyst is their origin. The blastocyst in the egg, the blastoid in the ES cells. There might be elements in the oocyte that are important for the viability of the blastocysts and that will not be provided by the ES cells. Furthermore, if about 50% of conceptions fail at implantation, it is difficult to gauge whether the failure of the high level goal of the experiment (long term development in the womb) is due to defects in the blastoid system or whether the failure mirrors the natural situation; eight experimental subjects, the numbers of the experiment, are not sufficient to make a judgement. Only more experiments will decide and the one reported here, within well established ethical footprints, is definitely one to watch.

Dr Darius Widera, Associate Professor in Stem Cell Biology and Regenerative Medicine, University of Reading, said:

This is an interesting study that demonstrates the successful generation of embryo-like structures from monkey embryonic stem cells. These structures resembled natural early embryonic structures and could generate cell types of all three germ layers. Although similar studies have been conducted using human stem cells, this is the first report showing that (in this case, monkey) embryo-like structures can induce signs of pregnancy if transplanted into females. Therefore, the method could be used as a model of primate and human development and potentially provide new insights into certain factors that contribute to miscarriages in humans.

However, the study has some limitations. Only 3 out of 8 embryo-like structures were successfully implanted into female monkeys, and none of these persisted for more than one week. Thus, the structures do not have full developmental potential.

In addition, the ethical implications of embryonic stem cell research in monkeys are complex. Primates are intelligent, social animals with complex cognitive and emotional lives. Therefore, it is important to carefully consider both the potential benefits and the ethical impact of primate embryonic stem cell research.

Prof Robin Lovell-Badge FRS FMedSci, Group Leader, Francis Crick Institute, said:

The paper by Jie Li et al is another demonstration of the remarkable ability of pluripotent stem cells, in this case embryonic stem cells derived from early Macaque (non-human primate) embryos, to self-organise and begin a process of embryo formation in culture that mirrors that of normal Macaque embryos. However, the paper also shows that these stem cell-based embryo models are not entirely normal they could be implanted in female macaques, appear to initiate a pregnancy, but then fail soon after.

The authors were able to culture these stem cell-based embryo models, which they refer to as blastoids, through to gastrulation stages, equivalent to post-implantation embryos developing in a uterus, with good signs of development of all the main extraembryonic and embryonic tissues, where the latter included ectoderm, mesoderm and endoderm organised in a similar fashion to normal embryos. They could also demonstrate the presence of primordial germ cell-like cells and cells that are early progenitors of the blood system. These stages would be equivalent to those of human embryos at about 16 -18 days of development, beyond the 14 day limit (or the beginning of gastrulation) which is the maximum period normal human embryos are allowed to be cultured by law in the UK and some other countries.

It has been shown by others that human pluripotent stem cells can also be used to form blastoids, but to date such cultures have been stopped prior to gastrulation, but the paper by Li et al suggests that they could indeed be taken beyond this and provide valuable information about these early stages of human development that are otherwise very difficult to obtain. The data from the Macaque embryos and blastoid cultures may also help to understand aspects of human development, but without direct comparisons this will always be tentative, given how much mammalian embryos can vary at these stages.

These embryo models are referred to as integrated stem cell-based embryo models because they include extraembryonic tissues that normally give rise to the placenta and yolk sac that in a normal conceptus would permit implantation into the uterus and support the development of the embryo proper. So how much like a real embryo are these Macaque blastoids and could they implant and develop much further in a uterus? Although all the detailed comparisons presented in the paper of gene expression in the various cell types between normal Macaque embryos and the embryo models suggests that they can be very similar, the proportion of the blastoids reaching advanced stages was very low, indicating that most are not normal, and those that did still showed some differences. Moreover, while some could implant, begin to develop some complexity, and induce a typical response in the host uterus and lead to production of the typical pregnancy hormones, chorionic gonadotrophin and progesterone, the embryos all failed before gastrulation. This suggests that they failed to form fully functional extraembryonic tissues that could adequately support the embryo and that these could not give rise to a placenta, which would be essential for more complex development. It is likely that the same would be true for human integrated stem cell-based embryo models, although it would be unethical and illegal (in the UK) to attempt to implant these into a woman.

It seems likely that the culture methods for these integrated stem cell-based embryo models will be improved, and who knows it may eventually be possible to have them implant and develop normally, but the failure of this to happen as reported in this paper will give regulators some breathing space to develop appropriate rules for the culture of such human models, notably whether they can be taken beyond the equivalent of gastrulation stages, which would be of immense importance in helping to understand not just normal development of the human embryo, but what so often goes wrong and leads to embryo failure and congenital disorders.

Cynomolgus monkey embryo model captures gastrulation and early pregnancy by Jie Li et al. was published in Cell Stem Cell at 16:00 UK time on Thursday 6 April 2023.

DOI: 10.1016/j.stem.2023.03.009

Declared interests

Prof Magdalena Zernicka-Goetz: I have no conflict of interest to declare.

Prof Roger Sturmey: None.

Prof Alfonso Martinez Arias: I have no conflict of interests.

Dr Darius Widera: I have no conflict of interest to declare.

Prof Robin Lovell-Badge: I have no conflicts of interest to declare, except I do serve on the HFEAs Scientific and Clinical Advances Advisory Committee and I am a member of their Legislative Reform Advisory Group.

The rest is here:
expert reaction to study looking at creating embryo-like structures ... - Science Media Centre

UCF Bone Researcher Receives National Recognition – UCF

As a child, Melanie Coathup enjoyed solving puzzles and had a deep fascination with science. Now an internationally recognized biomedical engineer, Coathup has been inducted to the American Institute for Medical and Biological Engineering (AIMBE) College of Fellows one of the highest professional distinctions accorded to a medical and biological engineer.

As head of the Biionix Cluster at UCF and professor of medicine, Coathups work focuses on orthopedic innovation developing new technologies and therapeutics to rebuild and repair bone tissues lost due to aging, cancer therapy, degenerative diseases such as osteoporosis, or exposure to environments like space orbit.

Being recognized by AIMBE for my research is so phenomenal, its difficult to fully capture with words. I am ecstatic, excited and inspired for the future, she says. Carrying out research is a humbling experience, as there are always ups and downs and often with more challenges than successes. Its been an immense pleasure to work with my amazing post-docs and students over the years to create this body of research.

Coathup was elected by her peers and members of the College of Fellows for pioneering research in developing biomaterials for orthopedics and providing International leadership in translational medicine. She was honored at a formal induction ceremony in Arlington, VA on March 27 one of 140 inductees to the College of Fellows Class of 2023.

AIMBE Fellows represent the top two percent of medical and biological engineers who have made outstanding contributions to engineering and medicine through research, practice, or education. Three are Nobel Prize laureates, and 11have received the Presidential Medal of Science and/or Technology and Innovation.

Associate Dean and Director of the Burnett School of Biomedical Sciences Griff Parks congratulated Coathup on her induction.

This award highlights both the outstanding research that is ongoing in her lab, as well as her long term commitment to training the next generation of biomedical scientists in areas of high impact to human health, he says.

Coathups research has led to new implant designs to replace bone lost to cancer, and the development of a new kind of synthetic bone material to help patients with skeletal injuries regenerate their tissue for a speedier recovery.

I have always had a deep fascination with medical science, she says. One of my earliest memories as a child was reading books on science along with a (failed) attempt to read and learn the entire medical dictionary.

Through the Biionix Cluster, Coathup leads amultidisciplinary team of researchers working to develop innovative materials, processes and interfaces for advanced medical implants, tissue regeneration, prostheses and other future high-tech products.

Before joining UCF, Coathup was a professor and researcher at University College Londons Institute of Orthopaedics and Musculoskeletal Science, serving as head of the Centre for Cell and Tissue Research. Born in the U.K., Dr. Coathup completed undergraduate studies in medical cell biology at the University of Liverpool, U.K. before furthering her knowledge with a Ph.D. in orthopedic implant fixation. A first-generation graduate, she is passionate about encouraging and inspiring future generations of scientists, particularly young women and was previously honored by UCF in March 2019 for Womens History Month.

Three weeks ago, I learned that a 6-year-old girl in Wales named Lilly who was researching me for a class project wouldnt believe that I was a doctor working in STEM, Coathup says. This was because she is a girl. She told her teacher that she had made a mistake and that I couldnt be a doctor. To Lilly, and all young girls, I want you to know that you can do it. Allow yourself to dream, and follow your beliefs, passion, and heart, and with hard work, you can achieve all. I look forward to celebrating your future successes.

Read more:
UCF Bone Researcher Receives National Recognition - UCF

PhenomeX to Participate in American Association of Cancer … – BioSpace

EMERYVILLE, Calif., April 7, 2023 /PRNewswire/ -- PhenomeX Inc. (Nasdaq: CELL), the functional cell biology company, today announcedits participation at the American Association of Cancer Research (AACR) Annual Meeting 2023 being held from April 14-19 at the Orange County Convention Center in Orlando, Fla. AACR brings together scientists, clinicians, other health care professionals, survivors, patients, and advocates to share the latest advances in cancer science and medicine through this year's meeting theme of "Advancing the Frontiers of Cancer Science and Medicine."

At the conference, PhenomeX, the new company recently formed through the combination of Isoplexis and Berkeley Lights, will showcase its IsoSpark and Beacon optofluidic platform technologies and workflows in booth #3444. Attendees will have a chance to explore demonstrations of the technologies and learn more about how PhenomeX's applications can provide unparalleled insights into cell function along the continuum of scientific discovery, bioprocessing, translational, and clinical research.

In addition, the AACR Annual Meeting covers the latest advances in cancer through a variety of poster and speaker presentations. This year, PhenomeX technologies are highlighted in nine poster presentations ranging from Polyfunctional Profiles and Cytokine Secretion Activity of Transgenic TCR-T cells and Anti-Cancer Macrophage-Based Cell Therapy to the Identification of Myeloma-Specific T Cell Receptors by Functional Single Cell Interaction Analyses.Some of the presenting abstracts include:

About PhenomeX Inc.

PhenomeX is empowering scientists to leverage the full potential of each cell and drive the next era of functional cell biology that will advance human health. We enable scientists to reveal the most complete insights on cell function and obtain a full view of the behavior of each cell. Our unique suite of proven high-throughput tools and services offer unparalleled resolution and speed, accelerating the insights that are key to advancing discoveries that can profoundly improve the prevention and treatment of disease. Our award-winning platforms are used by researchers across the globe, including those at the top 15 global pharmaceutical companies and approximately 85% of leading U.S. comprehensive cancer centers.

Forward-Looking Statements

To the extent that statements contained in this press release are not descriptions of historical facts regarding PhenomeX or its products, they are forward-looking statements reflecting the current beliefs and expectations of management. Such forward-looking statements involve substantial known and unknown risks and uncertainties that relate to future events, and actual results and product performance could differ significantly from those expressed or implied by the forward-looking statements. PhenomeX undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties relating to the Company's growth and continual evolution see the statements in the "Risk Factors" sections, and elsewhere, in our filings with the U.S. Securities and Exchange Commission.

View original content to download multimedia:https://www.prnewswire.com/news-releases/phenomex-to-participate-in-american-association-of-cancer-research-annual-meeting-2023-301792302.html

SOURCE PhenomeX

Go here to read the rest:
PhenomeX to Participate in American Association of Cancer ... - BioSpace

Inland Empire stem-cell therapy gets $2.9 million booster – UC Riverside

A new UC Riverside training program will help undergraduates transition into regenerative medicine careers, infusing the Inland Empire wraith expertise in cutting-edge trauma and disease treatments.

Guadalupe Ruiz,RAMP diversity and outreach director, left, and Huinan Hannah Liu, bioengineering professor and RAMP principal investigator. (Stan Lim/UCR)

The Research Training and Mentorship Program to Inspire Diverse Undergraduates toward Regenerative Medicine Careers, or RAMP, has received $2.9 million to work with multiple groups of students over the next five years. The grant comes from the California Institute for Regenerative Medicine, the states stem cell agency.

The overall goal of the program is to develop therapies for cells and tissues damaged by injury, trauma, or disease, including brain cells. Laboratory work will include tissue engineering but also research into techniques where the body uses its own biological systems, sometimes with help of engineered materials to rebuild tissues and organs.

UCR already had parts of a stem-cell career training pipeline in place. The university hosts STRIDE, a program offering local high school students opportunities to participate in laboratory research projects. In addition, the TRANSCEND program, directed by UCR molecular biology professor Prue Talbot, helps increase the number and diversity of Ph.D. and postdoctoral scientists trained in stem cell biology.

The missing link was undergraduates, said Huinan Hannah Liu, UCR bioengineering professor and RAMP principal investigator. RAMP is a linker molecule between those two programs.Interested undergrads are encouraged to apply.

Liu got involved with the program because her laboratory works on ways to improve cellular nutrient delivery and waste transport. A lot of metabolic waste in a cell impedes regeneration, Liu said. Nothing thrives in an environment full of waste.

Sometimes called the body's master cells, stem cells develop into blood, brain, bones, and all of the body's organs. They have the potential to repair, restore, replace, and regenerate cells. (luismmolina/iStock/Getty)

Her focus mirrors the first of three sub-specialties from which RAMP students will be able to choose. Faculty from UCRs Marlan and Rosemary Bourns College of Engineering will work with students to engineer materials that serve as scaffolds for growing cells and tissues.

Students can also choose to work with faculty from the College of Natural and Agricultural Sciences, who have expertise in cell biology. They understand the biological mechanisms behind tissue development, and the pathology of different disease stages, Liu said. Their collaboration with engineering faculty will be critical.

Faculty from UCRs School of Medicine will also work with students on ways to differentiate stem cells toward various cell types, and research the mechanisms of how cells and tissues function in the body. They can determine, for example, whether the body will accept an engineered cell, Liu said.

Moving forward, Liu is hopeful that RAMP will attract more clinical faculty, who can help do studies to test whether engineered materials, cells and tissues are safe before translating the work to human subjects.

Another key component of the program will be reaching out to patients and local communities to make them aware of new treatment options available to them. As they see the need in our area, Im hopeful these students will remain long term and help heal our diverse, underserved Inland Empire communities, Liu said.

(Cover image: stem cells: luismmolina/iStock/Getty)

Read the original:
Inland Empire stem-cell therapy gets $2.9 million booster - UC Riverside

New finding in roundworms upends classical thinking about animal cell differentiation – News-Medical.Net

Researchers have spotted how specific proteins within the chromosomes of roundworms enable their offspring to produce specialized cells generations later, a startling finding that upends classical thinking that hereditary information for cell differentiation is mostly ingrained within DNA and other genetic factors.

The Johns Hopkins University team reports for the first time the mechanisms by which a protein known as histone H3 controls when and how worm embryos produce both highly specific cells and pluripotent cells, cells that can turn certain genes on and off to produce varying kinds of body tissue. The details are published today in Science Advances.

The new research could shed light on how mutations associated with these proteins influence various diseases. In children and young adults, for example, histone H3 is closely associated with various cancers.

These mutations are highly prevalent in different cancers, so understanding their normal role in regulating cell fate and potentially differentiation of tissues may help us understand why some of them are more prevalent in certain diseases. The histones that we're looking at are some of the most mutated proteins in cancer and other diseases."

Ryan J. Gleason, lead author, postdoctoral fellow in biology at Johns Hopkins

Histones are the building blocks of chromatin, the structural support of chromosomes within a cell's nucleus. While histone H3 is particularly abundant in multicellular organisms such as plants and animals, unicellular organisms teem with a nearly identical variant of H3. That's why scientists think the difference in rations of H3 and its variant hold crucial clues in the mystery of why pluripotent cells are so versatile during early development.

The researchers revealed that as C. elegans roundworm embryos grew, increasing H3 levels in their systems restricted the potential or "plasticity" of their pluripotent cells. When the team changed the worm's genome to lower the amount of H3, they successfully prolonged the window of time for pluripotency that is normally lost in older embryos.

"As cells differentiate, you start to get a hundredfold histone H3 being expressed at that time period, which coincides with that lineage-specific regulation," Gleason said. "When you lower the amount of H3 during embryogenesis, we were able to change the normal path of development to adopt alternative paths of cell fate."

In pluripotent cells, histones help switch certain genes on and off to commit to specific cell types, be they neurons, muscles, or other tissue. Highly regulated by histones, genes act as a voice that tell cells how to develop. How quiet or loud a gene is determines a cell's fate.

The new findings come from the gene-editing technique CRISPR, which helped the team track the role the two histones played as the worm's offspring developed. CRISPR has made it much easier for scientists in the last decade to study the nuts and bolts of changing genetic material and spot what that does to animal, plant, and microbe traits, Gleason said.

Even though the C. elegans roundworm gives finer insights into how these pluripotent cells evolve, further research is needed to zero in on how histones might also underpin embryogenesis in humans and animals composed of hundreds of types of cells, said Xin Chen, a Johns Hopkins biology professor and co-investigator.

"Even though we are using this small worm to make these discoveries, really this finding should not be specific to one animal," Chen said. "It's hard to imagine the findings are only going to be applicable to one histone or one animal but, of course, more research needs to be done."

The team includes Yanrui Guo of Johns Hopkins, Christopher S. Semancik of Tufts University, Cindy Ow of University of California, San Francisco, and Gitanjali Lakshminarayanan of Dana-Farber Cancer Institute.

Source:

Journal reference:

Gleason, R. J., et al. (2023) Developmentally programmed histone H3 expression regulates cellular plasticity at the parental-to-early embryo transition. Science Advances. doi.org/10.1126/sciadv.adh0411.

Excerpt from:
New finding in roundworms upends classical thinking about animal cell differentiation - News-Medical.Net

Biology’s unsolved chicken-or-egg problem: Where did life come from? – Big Think

Biology has a chicken-or-egg problem. Two types of molecules are essential for life. Cells contain protein molecules, which perform most of the biochemical and physical functions. Cells also contain DNA and RNA molecules, which carry the blueprint information for making more cells. When life first arose on Earth 3.5 billion years ago, which came first: function or information? Its a major unsolved problem of how biology arose from prebiotic chemistry.

Some people think that life first got started call it Day One from RNA, because some RNA molecules can do double-duty and act like proteins. But, we believe proteins came first. The proteins-first perspective helps to solve another major mystery: Where did Darwinian evolution come from? We want to know not only what form of matter arose on Day One, but also why that matter would persist and adapt and go forward into Day Two, Day Three, and beyond.

Darwinian evolution is biologys planet-wide unrelenting drive to adapt, innovate, and change. Through survival of the fittest, organisms compete to win resources, beget other organisms, and adapt to their environments. Ever since Charles Darwin 160 years ago, we know much about how evolution works, but we have no idea how it got started. Evolution must have had a beginning. It is not a universal law, like the principles of physics or chemistry, which have operated since the beginning of the Universe. As far as we know, evolution has only been running since biology first arose about 3.5 billion years ago, a billion years after earth was formed.

Why would proteins come first? Proteins are most of a cells mass, so the differential growth rates that are the grist for the mill of cell evolution are largely a matter of differential protein production. And, proteins are the maker molecules that catalyze those growth reactions. Importantly, proteins are unique in having sequence > structure > function relationships. Most other polymers, including most RNAs, do not.

Proteins form specific folded structures, which are the bases for the molecular functions that create the actions and behaviors of the cell. Think of a proteins 20 amino acids as falling into roughly two classes: oil-like hydrophobic monomers and water-like polar monomers. Proteins fold up; that is, protein strings ball up in water into specific compact shapes because of the basic physics that oil avoids water that is, oily amino acids fold to be inside the ball, away from the surrounding water outside the protein. This makes proteins great catalysts. Folded proteins are miniature solids. Being a solid is exactly whats needed to catalyze chemical reactions, because catalyst atoms need to hold their places long enough to assist the reaction. Further, a 20-amino-acid alphabet spans a range of chemistries, so they catalyze a range of reactions.

But how did protein-making get started? First, we know from experiments that the amino acid building blocks of proteins plausibly could have existed on the early Earth. We also know there were simple catalysts that could initially link together amino acids into peptides minerals and clays or air-water surfaces will do. Short proteins, called peptides, are even found on some meteorites.

So, lets call the first catalyst the Founding Rock rock simply implying a site fixed in space, and founding implying that it was the first catalyst, before proteins themselves were catalysts, free-floating and capturable inside cells. However, proteins made on the Founding Rock would have been too short and possessed neither functions nor propagation principles nor specific informational sequences. How might these bio-like properties emerge from simple peptides? Emergence is when a small change in some parameter turns a simple behavior into a more complex one.

Our computer modeling tells a plausible story: A few of those little random peptides ball up in water from oil-water forces, creating stable folded surfaces, becoming primitive catalysts, and helping to elongate other chains. Foldcats are what we call such chains. Those sequences will be rare, extremely so. But, as is true in many such matters of statistical physics, the question is not how improbable the states are, but rather how cooperative they are. How might one molecular action enhance the next one, like a snowball growing as it rolls down a hill? It doesnt matter which was the first snowflake. It matters only what is the process of becoming a snowball. The foldcat hypothesis explains snowballing cooperativity and the tipping point going from chemistry to biology, and from molecules falling apart to their persistent growth.

Subscribe for a weekly email with ideas that inspire a life well-lived.

How might this all work? The few long chains that are made on the Founding Rock catalyze the making of even longer chains, producing additional stable and diverse catalysts. Thats because long chains fold more tightly, protecting their cores from chemical degradation. Short chains degrade faster. Longer chains win recycled amino acid monomers, slurping up more resources. Winner peptide molecules take all, as a beginning to Darwinian evolution.

A skeptic might claim that this violates the Second Law of Thermodynamics, but this is not correct. Long story short: While the Second Law says that dead matter tends toward equilibrium and degradation, the Second Law doesnt apply to things that are plugged in things like TV sets, that are driven away from equilibrium. In the foldcat hypothesis, whats plugged in is the peptide synthesis on the Founding Rock in the presence of plentiful amino acids. Thats the driver. It would generate huge amounts of junk peptides, and a very small number of foldable longer chains. But, thats all that is needed to get the snowball rolling.

In short, we believe that function (proteins) came before information (RNA). We know of no alternative, that is, no driving force for an information-first process. Rather than genes using proteins to make new genes, we believe that proteins use genes to make new proteins. And, the foldcat mechanism simply shows how the middleman the genes were simply not needed at first. Peptides made proteins as the first step toward the origin of life.

Read more from the original source:
Biology's unsolved chicken-or-egg problem: Where did life come from? - Big Think